- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00035880
Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease
June 23, 2005 updated by: Abgenix
A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease
Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.
Study Overview
Study Type
Interventional
Enrollment
95
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Fremont, California, United States, 94555
- Abgenix, Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Recipient of single allogeneic stem cell transplant from any donor type
- Time post transplant less than 100 days
- Received no treatment for GVHD other than steroids
Exclusion Criteria:
- Recipient of second allogeneic stem cell transplant or subsequent lymphocyte product from the donor post transplant
- IBMTR index less than A
- Received any murine product in the past
- Diagnosed with chronic GVHD
- Received Atgam later than day 10 post transplant
- Change to prophylactic regimen for acute GVHD within 72 hours of randomization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 1999
Study Completion
June 1, 2003
Study Registration Dates
First Submitted
May 6, 2002
First Submitted That Met QC Criteria
May 6, 2002
First Posted (Estimate)
May 7, 2002
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
July 1, 2003
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABX-CB-9906
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Graft Vs Host Disease
-
Dana-Farber Cancer InstituteBayer; Genzyme, a Sanofi CompanyCompleted
-
Rambam Health Care CampusWithdrawnFecal Microbiota Transplantation in Graft vs. Host DiseaseIsrael
-
Novartis PharmaceuticalsCompletedCorticosteroid Refractory Acute Graft vs Host DiseaseGermany, Japan, Saudi Arabia, Turkey, United Kingdom, Spain, Canada, Italy, Australia, Austria, France, Korea, Republic of, Hong Kong, Israel, Netherlands, Russian Federation, Denmark, Greece, Taiwan, Norway, Czechia, Bulgaria
-
Washington University School of MedicineCompletedGraft Vs Host Disease | Graft-versus-host-diseaseUnited States
-
Shenzhen University General HospitalRecruitingGraft Vs Host DiseaseChina
-
National Cancer Institute (NCI)TerminatedGraft vs Host Disease | Graft-Versus-Host Disease | Chronic Graft vs. Host DiseaseUnited States
-
Boston Children's HospitalBristol-Myers SquibbRecruitingGraft Vs Host DiseaseUnited States
-
Christopher DvorakRecruitingGraft Vs Host Disease | Graft-versus-host-diseaseUnited States
-
Fred Hutchinson Cancer CenterFacet BiotechUnknownGraft-vs-Host DiseaseUnited States
-
Rabin Medical CenterUnknownGraft Vs Host DiseaseIsrael
Clinical Trials on ABX-CBL
-
Caliway Biopharmaceuticals Co., Ltd.Completed
-
Caliway Biopharmaceuticals Co., Ltd.Completed
-
Caliway Biopharmaceuticals Co., Ltd.RecruitingSubcutaneous FatUnited States
-
Caliway Biopharmaceuticals Co., Ltd.CompletedSubcutaneous FatUnited States
-
Caliway Biopharmaceuticals Co., Ltd.CompletedA Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease LipomasDercum's DiseaseUnited States
-
Caliway Biopharmaceuticals Co., Ltd.Active, not recruiting
-
Abalonex, LLCNot yet recruitingTraumatic Brain Injury | Cerebral Edema
-
Caliway Biopharmaceuticals Co., Ltd.Completed
-
Caliway Biopharmaceuticals Co., Ltd.Completed
-
Caliway Biopharmaceuticals Co., Ltd.Not yet recruiting